A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy

S D Heys, I C Smith, J A S Ross, F J Gilbert, J Brooks, S Semple, I D Miller, A Hutcheon, T Sarkar, O Eremin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Work in an animal cancer model suggests that pretreatment with hyperbaric oxygen can improve tumor vascularity rendering chemotherapy more effective. Accordingly 32 subjects with locally advanced breast carcinoma (>5cm diameter) entered into a randomized clinical trial where a course was administered of six intravenous pulses of cyclophosphamide 1000mg/m2 i.v., doxorubicin 50mg/m2 i.v. and vincristine 1.5mg/m2 i.v. In the case group this was preceded by ten, once daily, sessions of hyperbaric oxygen therapy (HBO2) administered either at 2.4 or 2.0 atmospheres absolute. Eleven out of 15 subjects tolerated a full course of HBO2 and chemotherapy. All 17 control subjects tolerated a full course of chemotherapy. Tumor extravascular extracellular or edema fluid was reduced after HBO2 but there was no reduction in tumor cell volume and no indication of increased vascularity on MRI. Clinical and pathological responses to chemotherapy were the same in both groups and there was no evidence of neovascularisation. Five year survival in those who tolerated the trial regime was 73% and did not differ between the groups. This mortality was cancer related.
Original languageEnglish
Pages (from-to)33-43
Number of pages11
JournalUndersea & Hyperbaric Medicine
Volume33
Issue number1
Publication statusPublished - 2006

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Capillary Permeability
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Cyclophosphamide
  • Doxorubicin
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperbaric Oxygenation
  • Middle Aged
  • Neovascularization, Pathologic
  • Pilot Projects
  • Vincristine

Cite this

A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy. / Heys, S D; Smith, I C; Ross, J A S; Gilbert, F J; Brooks, J; Semple, S; Miller, I D; Hutcheon, A; Sarkar, T; Eremin, O.

In: Undersea & Hyperbaric Medicine, Vol. 33, No. 1, 2006, p. 33-43.

Research output: Contribution to journalArticle

Heys, SD, Smith, IC, Ross, JAS, Gilbert, FJ, Brooks, J, Semple, S, Miller, ID, Hutcheon, A, Sarkar, T & Eremin, O 2006, 'A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy', Undersea & Hyperbaric Medicine, vol. 33, no. 1, pp. 33-43.
Heys, S D ; Smith, I C ; Ross, J A S ; Gilbert, F J ; Brooks, J ; Semple, S ; Miller, I D ; Hutcheon, A ; Sarkar, T ; Eremin, O. / A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy. In: Undersea & Hyperbaric Medicine. 2006 ; Vol. 33, No. 1. pp. 33-43.
@article{26ee25ffd1b74c0f876ae6b7e0be5b8d,
title = "A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy",
abstract = "Work in an animal cancer model suggests that pretreatment with hyperbaric oxygen can improve tumor vascularity rendering chemotherapy more effective. Accordingly 32 subjects with locally advanced breast carcinoma (>5cm diameter) entered into a randomized clinical trial where a course was administered of six intravenous pulses of cyclophosphamide 1000mg/m2 i.v., doxorubicin 50mg/m2 i.v. and vincristine 1.5mg/m2 i.v. In the case group this was preceded by ten, once daily, sessions of hyperbaric oxygen therapy (HBO2) administered either at 2.4 or 2.0 atmospheres absolute. Eleven out of 15 subjects tolerated a full course of HBO2 and chemotherapy. All 17 control subjects tolerated a full course of chemotherapy. Tumor extravascular extracellular or edema fluid was reduced after HBO2 but there was no reduction in tumor cell volume and no indication of increased vascularity on MRI. Clinical and pathological responses to chemotherapy were the same in both groups and there was no evidence of neovascularisation. Five year survival in those who tolerated the trial regime was 73{\%} and did not differ between the groups. This mortality was cancer related.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capillary Permeability, Chemotherapy, Adjuvant, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Follow-Up Studies, Humans, Hyperbaric Oxygenation, Middle Aged, Neovascularization, Pathologic, Pilot Projects, Vincristine",
author = "Heys, {S D} and Smith, {I C} and Ross, {J A S} and Gilbert, {F J} and J Brooks and S Semple and Miller, {I D} and A Hutcheon and T Sarkar and O Eremin",
year = "2006",
language = "English",
volume = "33",
pages = "33--43",
journal = "Undersea & Hyperbaric Medicine",
issn = "1066-2936",
publisher = "Undersea and Hyperbaric Medical Society",
number = "1",

}

TY - JOUR

T1 - A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy

AU - Heys, S D

AU - Smith, I C

AU - Ross, J A S

AU - Gilbert, F J

AU - Brooks, J

AU - Semple, S

AU - Miller, I D

AU - Hutcheon, A

AU - Sarkar, T

AU - Eremin, O

PY - 2006

Y1 - 2006

N2 - Work in an animal cancer model suggests that pretreatment with hyperbaric oxygen can improve tumor vascularity rendering chemotherapy more effective. Accordingly 32 subjects with locally advanced breast carcinoma (>5cm diameter) entered into a randomized clinical trial where a course was administered of six intravenous pulses of cyclophosphamide 1000mg/m2 i.v., doxorubicin 50mg/m2 i.v. and vincristine 1.5mg/m2 i.v. In the case group this was preceded by ten, once daily, sessions of hyperbaric oxygen therapy (HBO2) administered either at 2.4 or 2.0 atmospheres absolute. Eleven out of 15 subjects tolerated a full course of HBO2 and chemotherapy. All 17 control subjects tolerated a full course of chemotherapy. Tumor extravascular extracellular or edema fluid was reduced after HBO2 but there was no reduction in tumor cell volume and no indication of increased vascularity on MRI. Clinical and pathological responses to chemotherapy were the same in both groups and there was no evidence of neovascularisation. Five year survival in those who tolerated the trial regime was 73% and did not differ between the groups. This mortality was cancer related.

AB - Work in an animal cancer model suggests that pretreatment with hyperbaric oxygen can improve tumor vascularity rendering chemotherapy more effective. Accordingly 32 subjects with locally advanced breast carcinoma (>5cm diameter) entered into a randomized clinical trial where a course was administered of six intravenous pulses of cyclophosphamide 1000mg/m2 i.v., doxorubicin 50mg/m2 i.v. and vincristine 1.5mg/m2 i.v. In the case group this was preceded by ten, once daily, sessions of hyperbaric oxygen therapy (HBO2) administered either at 2.4 or 2.0 atmospheres absolute. Eleven out of 15 subjects tolerated a full course of HBO2 and chemotherapy. All 17 control subjects tolerated a full course of chemotherapy. Tumor extravascular extracellular or edema fluid was reduced after HBO2 but there was no reduction in tumor cell volume and no indication of increased vascularity on MRI. Clinical and pathological responses to chemotherapy were the same in both groups and there was no evidence of neovascularisation. Five year survival in those who tolerated the trial regime was 73% and did not differ between the groups. This mortality was cancer related.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Capillary Permeability

KW - Chemotherapy, Adjuvant

KW - Combined Modality Therapy

KW - Cyclophosphamide

KW - Doxorubicin

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hyperbaric Oxygenation

KW - Middle Aged

KW - Neovascularization, Pathologic

KW - Pilot Projects

KW - Vincristine

M3 - Article

C2 - 16602255

VL - 33

SP - 33

EP - 43

JO - Undersea & Hyperbaric Medicine

JF - Undersea & Hyperbaric Medicine

SN - 1066-2936

IS - 1

ER -